STAT (8/28, Robbins) reports the FDA “has been quietly pressuring a handful of companies to stop reporting results to patients about how their genes may interact with specific drugs.” The agency is concerned that “amid a boom in genetic testing that aims to predict a person’s response to medication,…unsupported claims about gene-drug links could be dangerous, if they spur patients to start, stop, or switch medications in ways that aren’t appropriate.” The article highlights several examples of companies that have fallen under the FDA’s new scrutiny of pharmacogenetic testing.
Related Links:
— “FDA warns testing companies: Don’t tell patients how their DNA influences response to specific drugs, “Rebecca Robbins, STAT, August 28, 2019